Publications

Preclinical Efficacy

222

Modulation of inflammation-related genes in the cornea of a mouse model of dry eye upon treatment with cyclosporine eye drops

DAULL P (a), BARABINO S (b), FERAILLE L (c), KESSAL K (d), DOCQUIER (e), PARSADANIANTZ S (d), BAUDOUIN C (d,f), GARRIGUE JS (a)

Curr. Eye Res. 2019 Jan 21:1-10. doi: 10.1080/02713683.2018.1563197.

(a) SANTEN SAS, Evry, France - (b) OCULAR SURFACE & DRY EYE CENTER, University of Milan, Italy - (c) IRIS PHARMA, La Gaude, France - (d) INSTITUT DE LA VISION, Paris, France - (e) iGE3 Genomics Platform, University of Geneva, Switzerland - (f) Quinze-Vingts National Ophthalmology Hospital, Paris, France 

221

Chronic model of uveitis in rabbit - Efficacy of Triamcinolone Acetonide

QUENTRIC Y (a), ANTONELLI S (a), MAURO V (a), CIMBOLINI N (a), FERAILLE L (a), ELENA PP (a)

ARVO meeting 2019; Vancouver - CANADA. Invest. Ophthalmol. Vis. Sci. 2019; 60(9):800. doi:

(a) IRIS PHARMA, La Gaude, France

download the poster  access to the abstract

220

Efficacy of preservative-free cyclosporine emulsion eye drops in a mouse model of dry eye

DAULL P (a) , NAGANO T (b), OKADA S (b), GROS E (c), FERAILLE L (c), GARRIGUE JS (a)

ARVO meeting 2019; Vancouver - Canada. Invest. Ophthalmol. Vis. Sci. 2019; 60(9):292. doi:

(a) SANTEN SAS, Evry, France  - (b) SANTEN Ltd., Osaka, Japan - (c) IRIS PHARMA, La Gaude, France

access to the abstract

219

Dry Eye: Efficacy evaluation of two synthetic peptides from Chondrocyte Derived ExtraCellular Matrix (CDEM) in comparison to lifitegrast, cyclosporine A, diquafosol sodium and sodium hyaluronate in a murine model of dry eye

BAIK T (a), CHOI J (a), MIN K (a), FERAILLE L (b), RAYMOND E (b), ELENA PP (b)

ARVO meeting 2019; Vancouver - Canada. Invest. Ophthalmol. Vis. Sci. 2019; 60(9):291. doi:

(a) YUYU PHARMA, Seoul, The Republic of Korea - (b) IRIS PHARMA, La Gaude, France

access to the abstract

218

Comparison of inflammatory gene networks in dry eye between human and mouse

KESSAL K (a,b), DAULL P (c), FERAILLE L (d), CIMBOLINI N (d), LIANG H (a,b), DOCQUIER (e), BARABINO S (f), MELIK PARSADANIANTZ S (a), GARRIGUE JS (c), BAUDOUIN C (a,b), BAUDOUIN F (a,b)

ARVO meeting 2019; Vancouver - Canada. Invest. Ophthalmol. Vis. Sci. 2019; 60(9):274. doi:

(a) INSTITUT DE LA VISION, Paris, France - (b) Quinze-Vingts National Ophthalmology Hospital, Paris, France - (c) SANTEN SAS, Evry, France - (d) IRIS PHARMA, La Gaude, France - (e) iGE3 Genomics Platform, University of Geneva, Switzerland - (f) CLINICA OCULISTICA, Genova, Italy

access to the abstract

214

The uni-nephrectomized SDT fatty rat, a novel type 2 diabetic model of diabetic nephropathy, develops features of diabetic retinopathy over 10 weeks

BRIAND F (a), ANTONELLI S (b), MAURO V (b), CIMBOLINI N (b), SHINOHARA M (c), BROUSSEAU E (a), OHTA T (d), KAGEYAMA Y (c), FERAILLE L (b), SULPICE T (a)

ARVO meeting 2018; Hawaii - USA. Invest. Ophthalmol. Vis. Sci. 2018; 59(9):3573. doi:

(a) PHYSIOGENEX, Labege, France - (b) IRIS PHARMA, La Gaude, France - (c) CLEA Japan Inc., Tokyo, Japan - (d) JAPAN TOBACCO Inc., Osaka, Japan

download the poster     access to the abstract

210

Comparative efficacy of preservative-free anti-inflammatory eye drops in a mouse model of dry eye

GARRIGUE JS (a), CIMBOLINI N (b), KESSAL K (c),  GROS E (b), MAURO V (b), BARABINO S (d), BAUDOUIN C (c), DAULL P (a)

ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8): 800. doi:

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) INSTITUT DE LA VISION, Paris, France - (d) CLINICA OCULISTICA, Genoa, Italy

access to the abstract

209

Conditional self-knockout of otx2 mice: a new model for late-onset neuronal degeneration

ELENA PP (a), ANTONELLI S (a), MAURO V (a), CIMBOLINI N (a), LAMONERIE T (b), FERAILLE L (a)

ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8):4532. doi:

(a) IRIS PHARMA, La Gaude, France - (b) UNIVERSITE DE NICE, Nice, France

access to the abstract

208

Corneal transcriptome changes in a mouse model of dry eye

DAULL P (a), FERAILLE L (b), KESSAL K (c),  ELENA PP (b), BARABINO S (d), BAUDOUIN C (c), GARRIGUE JS (a)

ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8): 797. doi:

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) INSTITUT DE LA VISION, Paris, France - (d) CLINICA OCULISTICA, Genoa, Italy

access to the abstract

205

Norbixin Protects Retinal Pigmented Epithelium Cells and Photoreceptors against A2E-Mediated Phototoxicity In Vitro and In Vivo

FONTAINE V (a), MONTEIRO E (a), BRAZHNIKOVA E (a), LESAGE L (a), BALDUCCI C (b), GUIBOUT L (b), FERAILLE L (c), ELENA PP (c), SAHEL JA (a), VEILLET S (b), LAFONT R (b)

PLOS ONE 11(12): e0167793. doi: 10.1371/journal.pone.0167793

(a) INSTITUT DE LA VISION, Paris, France - (b) BIOPHYTIS, Paris, France - (c) IRIS PHARMA, La Gaude, France

access to the article

223

Efficacy of a preservative-free cationic emulsion vehicle eye drop in a mouse model of dry eye

QUENTRIC Y (a), DAULL P (b), FERAILLE L (a), ELENA PP (a), GARRIGUE JS (b)

ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. 2016; 57: 422. doi: 

(a) IRIS PHARMA, La Gaude, France - (b) NOVAGALI Innovation Center, SANTEN SAS, Evry, France

PosterAbstract

204

Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye

DAULL P (a), FERAILLE L (b), BARABINO S (c), CIMBOLINI N (b), GRILLO-ANTONELLI S (b), MAURO V (b) and GARRIGUE JS (a)

Exp. Eye Res. 2016 Oct 21; 153:159-164 

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) CLINICA OCULISTICA, Genoa, Italy

access to the article

201

SMA+ perivascular cells evaluation in VEGF induced blood-retinal barrier breakdown in rabbit model

ELENA PP (a), MAURO V (a), GRILLO-ANTONELLI S (a), CIMBOLINI N (a), VIAUD-QUENTRIC K (a) and FERAILLE L (a)

EVER meeting 2016; Nice - France.

(a) IRIS PHARMA, La Gaude, France

download the poster   ⇒ access to the abstract

200

Pre-clinical in vivo (animal) testing of ocular formulations and drug delivery systems

ELENA PP (a)

Ocular Drug Delivery; Berlin - Germany. Oral communication

(a) IRIS PHARMA, La Gaude, France

199

Comparative efficacy of cyclosporine eye drop formulations in a mouse model of dry eye

GARRIGUE JS (a), DAULL P (a), FERAILLE L (b) and BARABINO S (c)

ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. 2016; 57(12): 421. doi: 

(a) SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) CLINICA OCULISTICA, Genoa, Italy

access to the article

198

BIO201: a new drug candidate for the treatment of dry AMD

FONTAINE V (a), BRAZHNIKOVA E (a), MONTEIRO E (a), LESAGE L (a), BALDUCCI C (b), GUIBOUT L (b), FERAILLE L (c), ELENA PP (c), SAHEL JA (a), VEILLET S (b), LAFONT R (b)

ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. 2016; 57: 1119. doi:

(a) INSTITUT DE LA VISION, Paris, France - (b) BIOPHYTIS, Paris, France - (c) IRIS PHARMA, La Gaude, France

access to the article

196

Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping

DAULL P (a), FERAILLE L (b), ELENA PP (b) and GARRIGUE JS (a)

J. Ocul. Pharmacol. Ther. 2016; doi: 10.1089/jop.2015.0054

(a) SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France

access to the article

216

HL036337 Ophthalmic Solution: Topical TNF Blocker for Dry Eye Disease

Protein and AntiboPEGS meeting 2015 Boston, MA (collaboration)

HanAll BioPharma Co., Ltd, Seoul, Korea

195

Cationic emulsion of cyclosporine for the management of ocular surface inflammation: a preclinical evaluation

DAULL P (a), FERAILLE L (b), AMRANE M (a), ELENA PP (b) and GARRIGUE JS (a)

IOIS meeting 2015; San Francisco – USA

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France

194

Comparison of CKC- and BAK-cationic emulsions in a rat model of corneal wound healing

DAULL P (a), FERAILLE L (b), ELENA PP (b) and GARRIGUE JS (a)

EVER meeting 2015; Nice – France. Poster T034

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France

access to the abstract

193

Evaluation of a cyclosporine A ophthalmic ointment in an experimental mouse model of dry eye

CIMBOLINI N (a), GRILLO-ANTONELLI S (a), MAURO V (a), FERAILLE L (a) and ELENA PP (a)

EVER meeting 2015; Nice – France. Poster T031

(a) IRIS PHARMA, La Gaude, France

download the poster

192

Efficacy evaluation of a cationic emulsion of cyclosporine in a mouse model of dry eye

DAULL P (a), FERAILLE L (b), BARABINO S (c) and GARRIGUE JS (a)

ARVO meeting 2015; Denver, CO - USA. Invest. Ophthalmol. Vis. Sci. 2015; 56: 4468. doi:

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) CLINICA OCULISTICA, Genoa, Italy

access to the abstract

191

Effects of the multi-kinase inhibitor regorafenib on ocular neovascularization

KLAR J (d), BOETTGER M (a,d), FREUNDLIEB J (c), KELDENICH J (c), ELENA PP (b) and VON DEGENFELD G (d)

ARVO meeting 2015; DENVER, CO - USA. Invest. Ophthalmol. Vis. Sci. 2015; 56(7): 426.92. doi:

(a) Clinical Sciences Experimental Medicine, BAYER PHARMA AG, Wuppertal, Germany - (b) IRIS PHARMA, Nice, France - (c) BAYER PHARMA AG, Wuppertal, Germany - (d) Ophthalmology, BAYER PHARMA AG, Wuppertal, Germany

access to the abstract

190

Comparison of the effect of Dexamethasone and Prednisolone Acetate in a rat model of glucocorticoid-induced ocular hypertension following topical delivery

ELENA PP (a), CIMBOLINI N (a), GRILLO-ANTONELLI S (a), BOUZIN M (a), FERAILLE L (a), VIAUD-QUENTRIC K (a), NICOLAS MF (b), LAURENT S (c) and BLOT C (c)

ARVO meeting 2015; DENVER, CO - USA. ARVO e-abstract No. 2001 - Poster D0244

(a) IRIS PHARMA, Nice, France - (b) SANOFI R&D - LGCR, Vitry-sur-Seine, France - (c) SANOFI R&D - Ophthalmology Unit, Paris, France

access to the abstract

224

Systemic treatment with glutathione PEGylated liposomal methylprednisolone (2B3-201) improves therapeutic efficacy in a model of ocular inflammation

Invest. Ophthalmol. Vis. Sci 2014; 55: 2859. doi: (collaboration)

TO-BBB TECHNOLOGIES BV, Leiden, Netherlands

188

The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye

BARABINO S (a), GRILLO-ANTONELLI S (b), CIMBOLINI N (b), MAURO V (b) and BOUZIN M (b)

Invest. Ophthalmol. Vis. Sci. 2014; 55: 6499-6504 doi:10.1167/iovs.14-14548

(a) CLINICA OCULISTICA, Genoa, Italy - (b) IRIS PHARMA, Nice, France

access to the article

187

Two simple animal models of intraocular pressure elevation for testing therapeutic drugs in glaucoma

GRILLO-ANTONELLI S (a), CIMBOLINI N (a), FERAILLE L (a) and ELENA PP (a)

EVER meeting 2014; Nice – France. Poster T017

(a) IRIS PHARMA, Nice, France

download the poster   ⇒ access to the abstract

181

Dry eye: two experimental rodent models for drug development

CIMBOLINI N (a), ANTONELLI S (a), BARABINO S (b), FERAILLE L (a), MARGARON P (a) and ELENA PP (a)

TFOS meeting 2013; Taormina - Sicily - Italy

(a) IRIS PHARMA, Nice, France - (b) CLINICA OCULISTICA, Genoa, Italy

download the poster

180

Effects of cyclosporine in an experimental rat model of dry eye

CIMBOLINI N (a), ANTONELLI S (a), FERAILLE L (a), MARGARON P (a) and ELENA PP (a)

EVER meeting 2013; Nice – France. Poster S008

(a) IRIS PHARMA, Nice, France

download the poster   ⇒ access to the abstract

179

Impact of the routes of administration on the effects of cyclosporine in an experimental rat model of dry eye

CIMBOLINI N (a), GRILLO-ANTONELLI S (a), FERAILLE L (a), MARGARON P (a) and ELENA PP (a)

ISOPT meeting 2013; Paris – France

(a) IRIS PHARMA, Nice, France

download the poster

176

Comparison of two rodent models of dry eye induced by Scopolamine

ELENA PP (a), CIMBOLINI N (a), ANTONELLI S (a), FERAILLE L (a), BARABINO S (b) and MARGARON P (a)

ARVO meeting 2013; Seattle, WA - USA. ARVO e-abstract No. 6002 - Poster A0065

(a) IRIS PHARMA, Nice, France - (b) CLINICA OCULISTICA, Genoa, Italy

access to the abstract

173

Protection of blue light induced retinal degeneration by the free radical scavenger Phenyl-N-tert-butylnitrone and a serotonin receptor 5-HT1a agonist in rats

GRILLO-ANTONELLI S (a), CIMBOLINI N (a), DUBOS H (a), FERAILLE L (a), MARGARON P (a) and ELENA PP (a)

EVER meeting 2012; Nice - France. Poster S063

(a) IRIS PHARMA, Nice, France

download the poster   ⇒ access to the abstract

172

Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping

DAULL P (a), FERAILLE L (b), ELENA PP (b), BAUDOUIN C (c) and GARRIGUE JS (a)

EVER meeting 2012; Nice - France. Poster T036

(a) NOVAGALI PHARMA SA, Evry, France - (b) IRIS PHARMA, Nice, France - (c) INSTITUT DE LA VISION, Paris, France

access to the abstract

171

Ocular surface effects of antiglaucoma combination therapies in a rat model of corneal scraping

DAULL P (a), GARRIGUE JS (a), FERAILLE L (b), BAUDOUIN C (c) and ELENA PP (b)

EVER meeting 2012; Nice - France. Poster T037

(a) NOVAGALI PHARMA SA, Evry, France - (b) IRIS PHARMA, Nice, France - (c) INSTITUT DE LA VISION, Paris, France

access to the abstract

170

Multiple topical administrations of Ramipril enhance retinal ganglion cell survival after transient retinal ischemia-reperfusion in rats

ELENA PP (a), VIAUD-QUENTRIC K (a), CHARFEDDINE R (b), REKIK R (b)

EVER meeting 2012; Nice - France. Poster F029

(a) IRIS PHARMA, Nice, France - (b) UNIMED, Sousse, Tunisie - (c) Ophthalmology Clinic, Tunis, Tunisia

access to the abstract

168

Anti-inflammatory Effects Of Glucocorticoids On Endotoxin-induced Uveitis In Rats: Effects Of The Mode Of Administration

ELENA PP (a), CIMBOLINI N (a), ANTONELLI S (a), DUBOS H (a), FERAILLE L (a) and MARGARON P (a)

ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 6285 - Poster D1145

(a) IRIS PHARMA, Nice, France

download the poster   ⇒ access to the abstract

167

Assessment of Intra-Ocular Pressure lowering effect of novel gel formulations of Latanoprost and Timolol in nonhuman primates following topical delivery

GOODY RJ (a), WHITTAKER S (a), HENRY S (a), BROOKES R (a), STRUHARIK M (a), BERMON F (b), MARGARON P (b), POLZER H (c), LAWRENCE MS (a)

ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1968 - Poster D812

(a) RXGEN, Hamden, CT, USA - (b) IRIS PHARMA, Nice, France - (c) MEDPROJECT PHARMA, Bayern, Germany

access to the abstract

160

Ocular Distribution and Spectrum of Activity of a Fully Human Anti-Herpes Simplex Virus IgG Fab Fragment, Following Topical Application

BERDUGO-POLAK M (a,b), LARSEN IV (c), ABADIE C (d), KOWALCZUK L (a,b), TOUCHARD E (a,b), NELSON JD (e), ELENA PP (f), BRANDT CR (c), BEHAR-COHEN F (a,b,g), COMBETTE JM (d)

ARVO meeting 2010; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1991 - Poster D1028

(a) INSERM UMRS 872, Paris, France - (b) Pierre et Marie Curie University, Paris, France - (c) University of Wisconsin School of Medicine and Public Health, Madison, WI, USA - (d) RIBOVAX BIOTECHNOLOGIES, Petit-Lancy, Switzerland - (e) CALMUNE CORPORATION, San Diego, CA, USA - (f) IRIS PHARMA, Nice, France - (g) Hotel-Dieu University Hospital, Paris, France

access to the abstract

154

Corneal Effect of Topical Diclofenac co-Administration with Aminoside and Steroid in Rabbits

CAILLAUD T (a), VIAUD K (a), and ELENA PP (a)

ARVO meeting 2009; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1957

(a) IRIS PHARMA, Nice, France

download the poster

149

Immunohistochemistry and in situ Zymography to Assess Matrix Metalloproteinases Expression and Activation by Latanoprost in Rat Uveoscleral Pathway

ELENA PP (a), FRETON A (a), SPADAFORA A (a), GRILLO-ANTONELLI S (a), CIMBOLINI N (a), FERAILLE L (a), and LAZDUNSKI M (b)

ARVO meeting 2008; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2008; 49: 2616. doi:

(a) IRIS PHARMA, Nice, France - (b) IPMC-UMR 6097, Valbonne, France

access to the abstract

148

Cationic oil-in-water emulsion as an improved cyclosporine ocular vehicle for vernal keratoconjuctivitis sicca (VKC)

LAMBERT G (a) and RABINOVICH-GUILATT L (a)

ARVO meeting 2007; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2007, Vol.48, 2301. doi: (collaboration)

(a) NOVAGALI PHARMA SA, Evry, France

access to the abstract

141

In vivo characterization of the anti-inflammatory effect of a multikinase inhibitor targeting angiogenesis and inflammation

JENSEN L (a), HJARNAA P (a), FENSHOLDT J (a), ELENA PP (b), ABELL K (a) and PETERSEN TK (a)

8th World Congress on Inflammation 2007; Copenhagen, Denmark. Inflamm Res. 2007; 56(suppl.3): S443, abstract P07.21

(a) LEO PHARMA, Ballerup, Denmark - (b) IRIS PHARMA, Nice, France 

access to the abstract

128

Effects of Dexamethasone in a Rat model of choroidal neovascularization

FERAILLE L (a), GRILLO-ANTONELLI S (a), CIMBOLINI N (a), CAILLAUD T (a), AND ELENA PP (a)

Ocular Anti-Angiogenesis meeting 2006; London - United Kingdom

(a) IRIS PHARMA, Nice, France

download the poster

127

Variation of Krüppel-like factors levels in mouse corneal model of angiogenesis

CHIAMBARETTA F, DE GRAEVE F, FERAILLE L, NEZZAR H, MARCEAU G, DASTUGNE B, RIGAL D, ELENA PP AND SAPIN V

ARVO meeting 2005; Fort Lauderdale, FL. Invest. Ophthalmol. Vis. Sci. 2005; 46: ARVO e-abstract No. 2609

123

Variation of krüppel-like factors ARNm levels in a mouse corneal model of angiogenesis

CHIAMBARETTA F, NEZZAR H, FERAILLE L, DE GRAEVE F, MARCEAU G, ELENA PP, RIGAL D, DASTUGUE B AND SAPIN V

SFO meeting 2005; Paris – France. Abstract No. 380

116

PKC412 content in retina, choroid and plasma of pup mice with retinal neovascularization induced by hypoxic stimuli

ELENA PP (a), AMAR T (a), CAILLAUD T(a), WONG M (b) AND BIZEC JC (c)

ARVO meeting 2004; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 4053

(a) IRIS PHARMA, Nice, France - (b) NOVARTIS PHARMA, East Hanover, USA - (C) NOVARTIS PHARMA AG, Basel, Switzerland

access to the abstract

115

PKC412 reduces retinal neovascularization induced by hypoxic stimuli in pup mice

CAILLAUD T (a), AMAR T (a), OTTLECZ A (b), WONG M (c), LAMBROU GN (b) AND ELENA PP (a)

ARVO meeting 2004; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 4062

(a) IRIS PHARMA, Nice, France - (b) NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland - (c) NOVARTIS PHARMA, East Hanover, USA

access to the abstract

113

Potency and duration of action of synthetic P2Y2 receptor agonists on Schirmer scores in rabbits

YERXA BR (a), DOUGLASS JG (a), ELENA PP (b), CAILLAUD T (b), AMAR T (b), REDICK CC (a) AND PETERSON WM (a)

Adv. Exp. Med. Biol. 2002; 506: 261-265

(a) Inspire Pharmaceuticals, Durham, USA - (b) IRIS PHARMA, Nice, France

 access to the abstract

110

Topical ocular instillation of nitric oxide synthase inhibitors and intraocular pressure in rabbits

FLEISCHHAUER JC (a) , LIU R (a) , ELENA PP (b), FLAMMER J (a) AND HAEFLIGER IO (a)

Klin. Monatsbl. Augenheidkd. 2001; 218: 351-353

(a) Laboratory of Ocular Pharmacology and Physiology, Basel, Switzerland - (b) IRIS PHARMA, Nice, France

access to the abstract

108

Ocular distribution of CAT-152 after a single subconjunctival injection in a pigmented rabbit model of glaucoma filtration surgery

ELENA PP, MCFARLANE S, GLOVER DR, AMAR T AND CAILLAUD T

ARVO meeting 2001; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2001; 42: S544, abstract No. 2915

104

Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension

LACHERETZ F, BARBIER A, SERRADEIL-LE GAL C, ELENA PP, MAFFRAND J AND LE FUR G

J. Ocul. Pharmacol. Ther. 2000; 16: 203-216

access to the abstract 

103

Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits

PISELLA PJ (a,b), FILLACIER K (d), ELENA PP (e), DEBBASCH C (b,c) AND BAUDOUIN C (a)

Ophthalmic Res. 2000; 32: 3-8

(a) Department of Ophthalmology, Ambroise Paré Hospital, APHP, Paris, France - (b) Toxicology Laboratory, University of Paris-V René Descartes, Paris, France - (c) Department of Cellular Pharmacotoxicology, XV-XX Hospital, Paris, France - (d) Department of Ophthalmology, University of Nice, France - (e) IRIS PHARMA, Nice, France

access to the article

101

Evaluation of a novel carteolol eye-drops with alginic acid as long action promoter

TISSIE G, SEBASTIAN C, MAURIN F, SECHOY O, DRIOT JY, ELENA PP AND TRINQUAND C

EVER meeting 2000; Palma de Mallorca, Spain. Ophthalmic Res. 2000; 32(S2): 29, abstract No. 214

99

Potency and duration of action of synthetic P2Y2-receptor agonists on schirmer scores in rabbits

YERXA BR, DOUGLASS JG, ELENA PP, CAILLAUD T, AMAR T AND PETERSON WM

(3rd International Conference on the Lacrimal Gland, Tear Film and Dry Eye Syndromes Maui, HI - USA) Cornea 2000; 19: S138

97

Benefits of a vasopressin V2 receptor antagonist, SR 121463, in the treatment of ocular hypertension in the rabbit

SERRADEIL-LE GAL C, LACHERETZ F, BARBIER A, ELENA PP, PASCAL M, MAFFRAND JP AND LE FUR G

World Congress on Neurohypophysial Hormones. 1999; Edinburgh - UK

96

INS365, a P2Y2 receptor agonist, increases Schirmer scores in albino rabbits

YERXA BR, ELENA PP, CAILLAUD T, AMAR T AND EVANS R

ARVO meeting 1999; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1999; 40: S540, abstract No. 2848

95

Inflammation measurement and immunocharacterization of cell proliferation in an experimental model of proliferative vitreoretinopathy

BAUDOUIN C, KHOSRAVI E, PISELLA PJ, ETTAICHE M AND ELENA PP

Ophthalmic Res. 1998; 30: 340-350

access to the abstract

94

The effect of pneumoperitoneum on intraocular pressure in rabbits with α-chymotrypsin-induced glaucoma

LENTSCHENER C, LEVEQUE JP, MAZOIT JX AND BENHAMOU D

Anesth. Analg. 1998; 86: 1283-1288. (collaboration)

93

Activity of SR121463, a selective non-peptide vasopressine V2 receptor antagonist, in a rabbit model of glaucoma

LACHERETZ F, BARBIER A, SERRADEIL-LE GAL C, ELENA PP, MAFFRAND JP AND LE FUR G

(ISER 1998 Abstract No. 795; Paris - France) Exp. Eye Res. 1998; 67: S239

92

Protective effect of nicardipine, a calcium channel blocker on electroretinogram and retinal cytoskeletal damages after ischemia-reperfusion on the rat

FREDJ-REYGROBELLET D, CAILLAUD T AND ELENA PP

ARVO meeting 1998; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1998; 39: S993, abstract No. 4591

91

Comparison of efficacy between ketotifen and olopatadine eyedrops in allergic conjunctivitis

ELENA PP, AMAR T, FETZ A AND SCHOCH C

ARVO meeting 1998; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1998; 39: S549, abstract No. 2531

90

Ocular distribution of lomefloxacin 0.3 % after a single instillation in the infected eye of pigmented rabbits

ELENA PP AND JAUCH A

J. Ocul. Pharmacol. Ther. 1997; 13: 551-558

access to the abstract

89

Intraocular pressure effects of topical rilmenidine in ocular hypertensive animals and in healthy volunteers and glaucoma subjects

NORDMANN JP, ELENA PP AND VILAIN C

ISECOPP meeting 1997 Munich – Germany, p. 12

87

Analyse de l'inflammation et de la prolifération cellulaire intra-oculaires dans un modèle expérimental de prolifération vitréorétinienne

PISELLA PJ, BECQUET F, ELENA PP AND BAUDOUIN C

Ophtalmologie (France) 1997; 11: 369-371

86

Effects of different formulations of mitoxantrone (solutions, nanospheres, liposomes) on glaucoma surgery in rabbits

TILLEUL P, DENIS P, MAIGNEN F, ELENA PP, NORDMANN JP, LEVERGE R AND ROSTENE W

Ophthalmic Res. 1997; 29: 218-226

access to the abstract

85

Retinal damage and protection after ischemic injury in the rat: a reappraisal

ELENA PP, CAILLAUD T, AMAR T AND HARITON C

ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S888, abstract No. 4151

83

Rilmenidine: effect on intraocular pressure in alpha-chymotrypsin rabbits

AMAR T, NORDMANN JP, CASTAGNE I, VILAIN C AND ELENA PP

ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S814, abstract No. 3790

77

Pharmacokinetics of 0.1 % azelastine eyedrops, a histamine-H1-antagonist, with or without an induced allergic conjunctivitis

ELENA PP, KHOSRAVI E, BORBE H, HERBST M and PETER G

ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S1027, abstract No. 4719

76

Protection induced by isopropyl unoprostone treatment after retinal ischemic injury in the rat

MOREL MANDRINO P, CAILLAUD T, ELENA PP and HARITON C

ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S103, abstract No. 502

 

Preclinical Pharmacokinetics

213

Exploratory ocular surface distribution studies of azithromycin formulations based on semifluorinated alkanes

FISCHER K (a), GRILLENBERGER R (a), AMAR T (b), KRÖSSER S (a)

EVER meeting 2017; Nice, France. Acta Ophthalmologica. DOI: 10.1111/j.1755-3768.2017.0S029

(a) NOVALIQ GmbH, 69120 Heidelberg, Germany - (b)  IRIS PHARMA, La Gaude, France

download the poster  ⇒ access to the abstract

212

Oral administration of the 11bhydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study

SCHWAB D (a), STURM C (a), PORTRON A (a), FUERST-RECKTENWALD S (b), HAINZL D (c), JORDAN P (d), STEWART W (e), TEPEDINO M (f) and DUBINER H (g)

BMJ Open Ophth 2017;1:e000063. DOI: 10.1136/bmjophth-2016-000063 (collaboration)

(a) ROCHE INNOVATION CENTER, Clinical Pharmacology, Roche Pharmaceutical Research and Early Development, Basel, Switzerland - (b)  ROCHE INNOVATION CENTER, Translational Medicine, Roche Pharmaceutical Research and Early Development,Basel, Switzerland - (c) ROCHE INNOVATION CENTER, Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Basel, Switzerland (d) Department of Biometrics, Product development, Roche Pharmaceutical Research and Early Development, Basel, Switzerland - (e) PRN Pharmaceutical Research Network, LLC, Cheyenne, Wyoming, USA - (f) Cornerstone Eye Care, Division of Health Care, High Point, North Carolina, USA - (g) Eye Care Centers Management, Inc., Clayton Eye Center, Morrow, Georgia, USA

access to the article

206

Binding to ocular albumin as a half-life extension. Principle for intravitreally injected drugs: evidence from mechanistic rat and rabbit studies

FUCHS H (a) and IGNEY F (a)

J. Ocul. Pharmacol. Ther. 2017; DOI: 10.1089/jop.2016.0083 (collaboration)

(a) BOEHRINGER INGELHEIM PHARMA GmbH & Co. KG, Biberach an der Riss, Germany

185

Plasma and ocular pharmacokinetic study comparing 3 µL micro-drop to typical 40 µL drop volume of timolol 0.5% in pigmented rabbits

VAN DER HEIDEN H (a,b), AMAR T (c) and LICHTENAUEUR W (a)

ARVO meeting 2014; Orlando, FL - USA. Invest. Ophthalmol. Vis. Sci. April 2014, Vol.55, 453. doi:

(a) MU-DROP, Apeldoorn, Netherlands - (b) ZAMB, Hospital Pharmacy, Tilburg, Netherlands - (c) IRIS PHARMA, La Gaude, France

access to the abstract

184

Ocular pharmacokinetic study comparing ramipril and ramiprilat formulations administered orally or topically in pigmented rabbits

QUENTRIC Y (a), AMAR T (a), BARRE N (a), FERAILLE L (a) and REKIK R (b)

ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 2360 - Poster B0036

(a) IRIS PHARMA, La Gaude, France - (b) OPHTHALMOLOGY CLINIC, Tunis, Tunisia

160

Ocular distribution and spectrum of activity of a fully human anti-herpes simplex virus IgG fab fragment, following topical application

BERDUGO-POLAK M (a,b), LARSEN IV (c), ABADIE C (d), KOWALCZUK L (a,b), TOUCHARD E (a,b), NELSON JD (e), ELENA PP (f), BRANDT CR (c), BEHAR-COHEN F (a,b,g) and COMBETTE JM (d)

ARVO meeting 2010; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1991 - Poster D1028

(a) INSERM UMRS 872, Paris, France - (b) Pierre et Marie Curie University, Paris, France - (c) University of Wisconsin School of Medicine and Public Health, Madison, WI, USA - (d) RIBOVAX BIOTECHNOLOGIES, Petit-Lancy, Switzerland - (e) CALMUNE CORPORATION, San Diego, CA, USA - (f) IRIS PHARMA, La Gaude, France - (g) Hotel-Dieu University Hospital, Paris, France

access to the abstract

156

Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation

AKPEK EK (a), VITTITOW J (b), VERHOEVEN RS (b), BRUBAKER K (b), AMAR T (c), POWELL KD (d), BOYER JL (b) and CREAN C (b)

J. Ocul. Pharmacol. Ther. 2009; 25: 433-439

(a) THE WILMER EYE INSTITUTE, Johns Hopkins Hospital, Baltimore, USA - (b) INSPIRE PHARMACEUTICALS, Durham, USA - (c) IRIS PHARMA, Nice, France - (d) ENTHALPY ANALYTICAL, Durham, USA

access to the abstract

153

Snapshot test for investigating gels of anti-glaucoma compounds as topical formulations

ELENA PP (a), POLLIN C (a), BERMON F (a), AMAR T (a), CAILLAUD T (a) and POLZER H (b)

ARVO meeting 2009; Fort Lauderdale, FL - USA. ARVO e-abstract No. 6002

(a) IRIS PHARMA, Nice, France - (b) MEDPROJECT PHARMA, Bayern, Germany 

access to the abstract

152

Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits

AMAR T (a), CAILLAUD T (a) and ELENA PP (a)

Curr Eye Res. 2008; 33: 149-158

(a) IRIS PHARMA, Nice, France 

access to the abstract

226

Netildex versus Tobradex®: ocular pharmacokinetic/pharmacodynamic after a single dose and after one-day treatment in pigmented rabbits

CIVIALE C (a), BLANCO A (a), SUDANO-ROCCARO A (a), AMAR T (b) and MAZZONE M (a)

Invest. Ophthalmol. Vis. Sci. 2007; 48(13):4272. doi:

(a) SIFI SPA, Lavinaio-Aci San Antonio, Italy - (b) IRIS PHARMA, Nice, France 

access to the abstract

131

Pharmacokinetics of clonidine after a single application of transscleral iontophoresis in rabbits

CAILLAUD T (a), ROY P (b), VIAUD K (a) and ELENA PP (a)

ARVO meeting 2006; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2006; 47: ARVO e-abstract No. 5109

(a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France

130

Influence of solution composition and electrode design on transscleral iontophoresis delivery of dexamethasone disodium phosphate

ROY P (a), VIAUD K (b), CAILLAUD T (b) and ELENA PP (b)

ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5110

(a) EYEGATE, Paris, France - (b) IRIS PHARMA, Nice, France

access to the abstract

116

PKC412 content in retina, choroid and plasma of pup mice with retinal neovascularization induced by hypoxic stimuli

ELENA PP (a), AMAR T (a), CAILLAUD T (a), WONG M (b) and BIZEC JC (c)

ARVO meeting 2004; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 4053

(a) IRIS PHARMA, Nice, France - (b) NOVARTIS PHARMA, East Hanover, USA - (C) NOVARTIS PHARMA AG, Basel, Switzerland

access to the abstract

111

Alginic acid effect on carteolol ocular pharmacokinetics in the pigmented rabbit

TISSIE G (a), SEBASTIAN C (a), ELENA PP (b), DRIOT JY (a) and TRINQUAND C (a)

J. Ocul. Pharmacol. Ther. 2002; 18: 65-73

(a) LABORATOIRE BAUSCH & LOMB/CHAUVIN, Montpellier, France - (b) IRIS PHARMA, Nice, France

access to the abstract

108

Ocular distribution of CAT-152 after a single subconjunctival injection in a pigmented rabbit model of glaucoma filtration surgery

ELENA PP, MCFARLANE S, GLOVER DR, AMAR T and CAILLAUD T

ARVO meeting 2001; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2001; 42: S544, abstract No. 2915

102

Localisation of Venoruton in rat blood vessel after single oral administration

SALLIN D, ELENA PP and ZIJLSTRA J

14th World Congress ot the 'Union Internationale de Phlebologie' Roma - Italy 2000

100

Alginic acid effect on ocular distribution of carteolol after a single instillation in pigmented rabbits

SEBASTIAN C, TISSIE G, DRIOT JY, ELENA PP and TRINQUAND C

EVER meeting 2000; Palma de Mallorca, Spain. Ophthalmic Res. 2000; 32(S2): 28, abstract No. 215

90

Ocular distribution of lomefloxacin 0.3 % after a single instillation in the infected eye of pigmented rabbits

ELENA PP and JAUCH A

J. Ocul. Pharmacol. Ther. 1997; 13: 551-558

access to the abstract

84

Ocular distribution of Rescula® Eye-Drops in the pigmented rabbit after a single topical administration

CAILLAUD T, AMAR T, HARITON C and ELENA PP

ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S815, abstract No. 3796

77

Pharmacokinetics of 0.1 % azelastine eyedrops, a histamine-H1-antagonist, with or without an induced allergic conjunctivitis

ELENA PP, KHOSRAVI E, BORBE H, HERBST M and PETER G

ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S1027, abstract No. 4719

74

Ocular bioavailability of ganciclovir gel, an anti-herpetic formulation, after topical administration to intact or removed corneal epithelium of rabbit eyes

KHOSRAVI E, ELENA PP, GOLDSCHMIDT P and LUYCKX J

ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S81, abstract No. 383

69

Lomefloxacin distribution after a single instillation in the infected eye of pigmented rabbits

KHOSRAVI E, ELENA PP and JAUCH A

ISECOPP meeting 1995 Geneva - Switzerland, p. 67

62

Ocular distribution of nicergoline after intravenous administration in rats

ELENA PP, BERTHOLOM N and KHOSRAVI E

JERMOV meeting 1994; Montpellier - France, p 173, abstract No. P12

60

Distribution of ganciclovir in the anterior uvea after topical application of 0.15 % ganciclovir gel to intact and HSV-infected eyes of rabbits

ELENA PP, GOLDSCHMIDT P, CHAST F, SAUVAGEON H, LUYCKX J and KHOSRAVI E

ARVO meeting 1994; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1994; 35: 1682, abstract No. 1984

55

Ocular pharmacokinetics of topically-applied ganciclovir in rabbits with intact or removed corneal epithelium

CHIBRET H, ELENA PP and KHOSRAVI E

ARVO meeting 1993; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1993; 34: 1050, abstract No. 1712

53

Piribédil: affinité pour les récepteurs dopaminergiques rétiniens et profil pharmacocinétique oculaire

LAPALUS P (a), DENIS P (b), DRICI M (a), FREDJ-REYGROBELLET D (a) and ELENA PP (c)

J. Neur. 1993; 240 (Suppl 1): S17-S21

(a) School medicine, dep. pharmacology, Nice, France - (b) Hôpital Saint-Antoine, Paris, France - (c) IRIS PHARMA, Nice, France 

access to the abstract

52

Retinal dopaminergic receptor affinity and ocular pharmacokinetic profile of piribedil

LAPALUS P, DENIS P, DRICI M, FREDJ-REYGROBELLET D and ELENA PP

J. Neurol. 1992; 239 (Suppl 1): S17-S21

access to the abstract

51

Ocular pharmacokinetics of trimetazidine in the pigmented rat after a single oral administration

ELENA PP, KHOSRAVI E, LAPALUS P, JOULIN Y and HARPEY C

ISER meeting 1992; Stresa - Italy. Exp. Eye Res. 1992; 55: S55, abstract No. 184

49

Ocular pharmacokinetics of two preservatives, benzalkonium chloride or benzoxonium chloride, after instillation in the pigmented rabbit

ELENA PP, KHOSRAVI E, LAPALUS P and ULRICH E

ISER meeting 1992; Stresa - Italy. Exp. Eye Res. 1992; 55: S54, abstract No. 182

48

Preclinical pharmacokinetics of the 14C-labelled aldose reductase inhibitor methosorbinil (E-0722)

ELENA PP, KUNZ PA and LAPALUS P

SOE meeting 1992, Brussels - Belgium. P. 188, abstract No. 737

37

Ocular pharmacokinetics of ganciclovir gel after a single administration

LAPALUS P, ETTAICHE M, LUYCKX J and ELENA PP

AER meeting 1990, Bad Honnef - Germany. P. 58, abstract No. 94

36

Hymecel pharmacokinetics after a single intracameral injection in phakic and aphakic eyes of pigmented rabbits

ELENA PP, LAPALUS P, FREDJ-REYGROBELLET D, ETTAICHE M and ULRICH E

AER meeting 1990, Bad Honnef - Germany. P. 25, abstract No. 6

32

Retinal dopaminergic receptors and distribution of piribedil

LAPALUS P, ELENA PP, FREDJ-REYGROBELLET D and DENIS P

ENS meeting 1990, Brighton - UK

29

Pharmacokinetic and autoradiographic studies of basic fibroblast growth factor on de-epithelialized and intact rabbit eye

FREDJ-REYGROBELLET D, ELENA PP, MOENNER M, BAUDOUIN C, ETTAICHE M, BARRITAULT D and LAPALUS P

Curr. Eye Res. 1989; 8: 1141-1152

20

Pharmacokinetics of topically-administered aldose reductase inhibitor (E-0722) on pigmented rabbit eye

LAPALUS P, FREDJ-REYGROBELLET D and ELENA PP

AER meeting 1989, Montpellier - France. Doc. Ophthalmol. 1990; 76: 129-130, abstract No. 45

19

Pharmacokinetic and autoradiographic studies of basic fibroblast growth factor on de-epithelialised and intact rabbit eye

FREDJ-REYGROBELLET D, ELENA PP, MOENNER M, BAUDOUIN C, ETTAICHE M, BARRITAULT D and LAPALUS P

AER meeting 1989, Montpellier - France, Doc. Ophthalmol. 1990; 76: 111, abstract No. 13

3

Etude cinétique d'un anti-allergique, le 14C-T86 en instillation chez le lapin albinos

LAPALUS P, MOULIN G, BAYER V, ELENA PP, NICOLAS C and LAPALUS F

J. Biophys. Med. Nucl. 1984; 8: 195-198

2

Etude cinétique d'un anti-allergique, le 14C-T86, en instillation chez le lapin albinos

LAPALUS P, MOULIN G, BAYER V, ELENA PP, NICOLAS C and LAPALUS F

Congrès de Médecine Nucléaire de Langue Francaise; Nice - France 1984

 

Ocular toxicity & toxicology

215

Safety and Tolerability of Overdosed Artificial Tears by Abraded Rabbit Corneas

DAULL P (a), RAYMOND E (b), FERAILLE L (b), GARRIGUE JS (a)

J. Ocul. Pharmacol. Ther. 2018; DOI: 10.1089/jop.2018.0040

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France

access to the abstract

227

Ocular tolerance in rabbits after intracameral administration of a fixed combination of tropicamide, phenylephrine, and lidocaine with and without rinsing

NUIJTS R (a), MENCUCCI R (b), VIAUD-QUENTRIC K (c), ELENA PP (c), OLMIERE C (d) and BEHNDIG A (e)

J. Cataract Refr. Surg. 2017; 43: 673-679. DOI: 10.1016/j.jcrs.2017.03.025

(a) Maastricht Universitair Medisch Centrum, the Netherlands – (b) University of Florence, Italy – (c) IRIS PHARMA, La Gaude, France – (d)  LABORATOIRES THEA, Clermont-Ferrand, France – (e) Umeå University, SWEDEN/span>

207

Safety evaluation of cationic emulsions following refractive surgery procedures

QUENTRIC Y (a), DAULL P (b), GROS E (a), ANTONELLI S (a), MAURO V (a), FERAILLE L (a), GARRIGUE JS (b)

ARVO meeting 2017; Baltimore - USA. ARVO e-abstract No. 5297 - Poster B0250

(a) IRIS PHARMA, La Gaude, France - (b) NOVAGALI Innovation Center, SANTEN SAS, Evry, France

access to the poster

202

Ocular tolerance in rabbits of intracameral administration of MYDRANE, a fixed combination of tropicamide, phenylephrine, and lidocaine for cataract surgery

OLMIERE C (a), VIAUD K (b)

EVER meeting 2016; Nice - France.

(a) LABORATOIRES THEA, Clermont-Ferrand, France - (b) IRIS PHARMA, Nice, France 

access to the abstract

197

Long-term tolerance of preservative-free eye drops containing macrogol hydroxystearate as an excipient

Tolérance à long terme d’un collyre sans conservateur contenant comme excipient du macrogol hydroxystearate

VIAUD K (a), LEFRANC-JULLIEN S (a), FERAILLE L (a) and ELENA PP (a)

J. Fr. Ophtalmol. 2015; Doi : 10.1016/j.jfo.2015.09.011

(a) IRIS PHARMA, Nice, France 

access to the abstract

189

In vivo ocular tolerance of a new preservative-free eye drop formulation in rabbits

QUENTRIC Y (a), VIAUD K (a), LEFRANC-JULLIEN S (a), FERAILLE L (a) and ELENA PP (a)

ARVO meeting 2015; Denver, CO - USA. ARVO e-abstract No. 802 - Poster D0264

(a) IRIS PHARMA, Nice, France 

download the poster   ⇒ access to the abstract

183

Safety and tolerability of drugs within the suprachoroidal space in albino rabbits

PATEL S (a), VERHOEVEN R (a), BURKE B (a), CACCIAMANI F (b), VIAUD-QUENTRIC K (b) and EDELHAUSER H (c,a)

ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 4886 - Poster C0082

(a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France - (c) EMORY UNIV EYE CENTER, Atlanta, GA, USA

178

CLS suprachoroidal injectable suspension of triamcinolone acetonide is well tolerated in the albino rabbit

VERHOEVEN R (a), VIAUD-QUENTRIC K (b), CACCIAMANI F (b) and PATEL S (a)

American College of toxicology 2013 San Antonio, Texas - USA. Poster P505

(a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France

177

Suprachoroidal microinjection of triamcinolone acetonide is well tolerated in the albino rabbit

VERHOEVEN R (a), PATEL S (a),  VIAUD-QUENTRIC K (b), CACCIAMANI F (b), AMAR T (b) and YERXA B (a)

ARVO meeting 2013; Seattle, WA - USA. ARVO e-abstract No. 119 - Poster C0124

(a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France

access to the abstract

154

Corneal effect of topical diclofenac co-administration with aminoside and steroid in rabbits

CAILLAUD T (a), VIAUD K (a), and ELENA PP (a)

ARVO meeting 2009; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1957

(a) IRIS PHARMA, Nice, France

download the poster

147

Ocular tolerability of iontophoresis

ROY P (a), ELENA PP (b), VIAUD K (b), CAILLAUD T (b) and CALIAS P

ARVO meeting 2007; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5800

(a) EYEGATE PHARMACEUTICALS, Waltham, USA - (b) IRIS PHARMA, Nice, France

129

Evaluation of ocular tolerability of repetitive corneal-scleral iontophoresis in pigmented rabbits

ELENA PP (a), ROY P (b), VIAUD K (a) and CAILLAUD T (a)

ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5094

(a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France

66

Lack of cytotoxic effect of ganciclovir and acyclovir on rabbit corneal epithelial cells in vitro

KHOSRAVI E, ELENA PP, GOLDSCHMIDT P, BAUDOUIN C and LUYCKX J

JERMOV meeting 1995; Montpellier - France. Vision Res. 1995; 35: S173, abstract No. P125

38

Cytotoxicity studies in ophthalmology

LAPALUS P, ETTAICHE M, FREDJ-REYGROBELLET D, JAMBOU D and ELENA PP

Lens Eye Toxic Res. 1990; 7: 231-242

 

Clinical Research

217

Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study

ECONOMOU M (a), KOLSTAD LAUKELAND H (b,c), GRABSKA-LIBEREK I (d), ROULAND JF (e)

Clinical Ophthalmol. 2018; 12: 2399–2407 (collaboration)

(a) St Erik’s Eye Hospital, Stockholm, Sweden - (b) University Hospital, Trondheim, Norway - (c) Norwegian University of Science and Technology, Trondheim, Norway - (d) Ophthalmology Clinic Postgraduate Centre of Medical Education, Warszawa, Poland - (e) Claude Huriez Hospital, Lille, France

access to the article

159

Dry Eye Syndrome : the regulatory challenge. Clinical trial and regulatory challenges faced by Iris Pharma in the development of dry eye therapies

QUENTRIC Y (a)

TFOS Global Dry Eye Experts' meeting 2010; Florence - Italy. Oral Communication

(a) IRIS PHARMA, Nice, France

155

Associer les patients atteints de DMLA à la recherche, est-ce possible?

BENCHABOUNE M (a)

Vu et Entendu. 2009; 2: 4

(a) IRIS PHARMA, Nice, France

access to the article

151

Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5%, 1.0%, and 1.5% eyedrops (T1225) in healthy volunteers

CHIAMBARETTA F, GARRAFFO R, ELENA PP, POULIQUEN P, DELVAL L, RIGAL D, DUBRAY C, GOLDSCHMIDT P, TABBARA K and COCHEREAU I

Eur. J. Ophthalmol. 2008; 18(1): 13-20

access to the abstract

144

Trend of prescription of silicon hydrogel lens by ophthalmologists and lens assessment by patients

CROS BOIDEVEZI M (a), STEVE L (a), JOUVENCEL R (a) and CLIROPHTHA (b)

29th IEEE EMBS Annual International Conference 2007; Lyon - France

(a) CIBA VISION France, Paris, France - (b) CLIROPHTHA, Nice, France

143

A new method for intra ocular pressure in vivo measurement: first clinical trials

DUBOIS P, ZEMMOURI J, ROULAND JF, ELENA PP, LOPES R and PUECH P

29th IEEE EMBS Annual International Conference 2007; Lyon - France

139

Improvement of dry eye symptoms with polyunsaturated fatty acids

GARCHER C, PASSEMARD M, LAFONTAINE PO, VIAU S, JOFFRE C, ELENA PP, POULIQUEN P, BAUDOUIN C and BRON AM

Acta Ophthalmologica Scandinavica. 2006; 84 Supplement 239: 135

138

Amélioration de la symptomatologie chez des patients atteints de sécheresse oculaire et traités oralement par des acides gras polyinsaturés. Improvement of dry eye symptoms with polyunsaturated fatty acids

GARCHER C, PASSEMARD M, VIAU S, JOFFRE C, LAFONTAINE PO, ELENA PP, POULIQUEN P, BAUDOUIN C and BRON AM

SFO meeting 2006; Paris - France (Oral communication No. 220)

137

Enquête prospective, nationale, multicentrique auprès de 345 patients anciens et nouveaux porteurs sur la santé oculaire, la performance visuelle et la satisfaction des lentilles 02 OPTIX TORIC

DELFOUR-MALECAZE M (a), STEVE L (b) and CLIROPHTHA (c)

Réflexions Ophtalmol. 2006; 95: 50-53
(a) Toulouse, France (b) CIBA VISION France, Paris, France - (c) CLIROPHTHA, Nice, France

136

Improvement of dry eye symptoms with polyunsaturated fatty acids

CREUZOT C, PASSEMARD M, VIAU S, JOFFRE C, POULIQUEN P, ELENA PP, BRON A and BRIGNOLE F

J. Fr. Ophtalmol. 2006; 29(8): 868-73

access to the article

135

Trend of prescription of silicone hydrogel lens by ophthalmologists and lens assessment by patients

CROS BOIDEVEZI M (a), STEVE L (a), JOUVENCEL R (a) and CLIROPHTHA (b)

36th ECLSO Congress 2006; Dubrovnik - Czech Republic. Abstract No. 9

(a) CIBA VISION France, Paris, France - (b) CLIROPHTHA, Nice, France

134

Etude comparative des implants Alcon asphériques (SN60WF) versus standards (SN60AT)

MONTARD M

Safir meeting 2006. Paris - France (collaboration)

133

Improvement of dry eye symptoms with polyunsaturated fatty acids

GARCHER C (a), PASSEMARD M (a), LAFONTAINE PO (a), VIAU S (b), JOFFRE C (b), ELENA PP (c), POULIQUEN P (d), BAUDOUIN C (e) and BRON AM (a)

EVER meeting 2006; Vilamoura - Portugal. Free paper No. 3155 and poster No. 335

(a) Hopital General, Dijon, France - (b) INRA - Eye and Nutrition Unit, Dijon, France (c) CLIROPHTHA, Nice, France (d) LABORATOIRES THEA, Clermont-Ferrand, France - (e) CHNO XV-XX, Paris, France

access to the abstract

132

Improvement of dry eye symptoms with polyunsaturated fatty acids

GARCHER C, PASSEMARD M, LAFONTAINE PO, VIAU S, JOFFRE C, ELENA PP, POULIQUEN P, BAUDOUIN C and BRON AM

ARVO meeting 2006; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2006; 47: ARVO e-abstract No. 236

126

Regard® : une enquête sur la tolérance et le confort oculaire d'une solution d'entretien pour lentilles de contact sans conservateur

MALET F and CLIROPHTHA

Réflexions Ophtalmol. 2005; 84: 62-65

125

Une nouvelle méthode de mesure de la pression intraoculaire

DUBOIS P (a), ZEMMOURI J (b), ROULAND JF (c) and ELENA PP (d)

IRBM 26; 4: 285-290

(a) Institut de technologie médicale, CHRU, Lille, France - (b) Laboratoire de spectroscopie hertzienne, USTL, Villeneuve d’Ascq, France - (c) Hôpital Huriez, Lille, France - (d) IRIS PHARMA, Nice, France

access to the abstract

124

Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients

RENARD P (a), KOVALSKI JL (b), COCHEREAU I (c), JAULERRY S (d), WILLIAMSON W (e), ELENA PP (f), LABLACHE COMBIER M (g), ALLAIRE C (g) and SIOU-MERMET R (g)

Graefe's Arch. Clin. and Exp. Ophthalmol. 2005; 243: 1221-1227

(a) Institut Vernes, Paris, France - (b) HIA Clermont Tonnerre, Brest, France - (c) CHRU, Angers, France - (d) CH Tarbes Vic Bigorre, Tarbes, France - (e) CH François Mitterrand, Pau, France - (f) IRIS PHARMA-CLIROPHTHA, Nice, France - (g) BAUSCH & LOMB, Paris, France

access to the abstract

203

Efficacy and safety of three ophthalmic inserts for topical anaesthesia of the cornea. An exploratory comparative dose-ranging, double-blind, randomized trial in healthy volunteers

MAHE I (a), MOULY S (a), JARRIN I (a), OTERO J (a), TAVERA C (b), SIMONEAU G (c), TILLET Y (c), CONTI R (b), EL MESKI S (b), GAUDRIC A (a), JF BERGMANN (a)

Br. J. Clin. Pharmacol. 2004; 59:2 220 – 226 (collaboration)

(a) Hôpital Lariboisière, Paris, France - (b) IOLTECH, La Rochelle, France - (c) WHITE-TILLET Consultants, Chelles, France

access to the article

122

Ocular hypotensive effect of a new “once-daily” eye-dops formulation of 0.5% timolol (Timolast™) in comparison to Timoptol® 0.5% administered twice-daily

ROULAND JF (a), MOREL-MANDRINO P (b), ELENA PP (b), DE GREGORIO F (c), BAROZZI C (c), FEDELI E (c) and FERREIRA VD (c)

ISOPT meeting 2004; Monte-Carlo – Monaco

(a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) TUBILUX PHARMA SpA, Roma, Italy

121

Intérêt d’une nouvelle formulation de diclofénac sans conservateur pour la surface oculaire

CHIAMBARETTA F (a), CREUZOT-GARCHER C (b), PILON F (a), POULIQUEN P (c), REBIKA H (c), DUBRAY C (d) and RIGAL D (a)

J. Fr. Ophtalmol. 2004; 27, 7, 739-744 (collaboration)

(a) Hôpital Gabriel Montpied, Clermont-Ferrand, France - (b) CHU de Dijon, Dijon, France - (C) LABORATOIRES THEA, Clermont-Ferrand, France - (d) Unité de Pharmacologie Clinique, Centre de Recherche en Nutrition Humaine, Clermont-Ferrand, France

access to the article

120

Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost

BRON A, VELASQUE L, REBICA H, POULIQUEN P, ELENA PP and ROULAND JF

J. Fr. Ophtalmol. 2004; 27(9 Pt 1): 971-7

access to the abstract

119

Non-inferiority, in the intra-ocular pressure (IOP)-lowering effect, of a new eye-drops formulation of 0.5% timolol (Timolast™) instilled once-daily versus 0.5% Timoptol®, instilled twice-daily, for 4 months in ocular hypertensive or glaucomatous patients

ROULAND JF (a), MOREL-MANDRINO P (b), DE GREGORIO F (c), BAROZZI C (c) and FEDELI E (c)

ARVO meeting 2004; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2004; 45(13): 2080. doi:

(a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) TUBILUX PHARMA SpA, Roma, Italy

access to the abstract

118

Comparison of carteolol plasmatic levels after repeated instillations of long acting and regular formulations of carteolol 2% in glaucomatous patients

ALLAIRE CM, RENARD P, KOVALSKI J, COCHEREAU I, JAULERRY S, WILLIAMSON W, ELENA PP and LABLACHE-COMBIER M

ARVO meeting 2004; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 957

117

Efficacy and safety of diclofenac 0.1% ABAK® versus preserved diclofenac® 0.1% eye drops in controlling post-cataract surgery inflammation

GOLDSCHMIDT P, ELENA PP, BALDWIN H, DELVAL L and COLIN J

ARVO meeting 2004; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 294

112

Timolol 0.1% Gel (Nyogel 0.1%®) Once Daily versus Conventional Timolol 0.5% Solution Twice Daily: A Comparison of Efficacy and Safety

ROULAND JF (a), MOREL-MANDRINO P (b), ELENA PP (b), POLZER H (c) and SUNDER RAJ P (d)

Ophthalmologica 2002; 216: 449-454

(a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) MEDPROJECT PHARMA, Sauerlach, Germany - (d) NOVARTIS OPHTHALMICS, Farnborough, UK

access to the abstract

109

A Novel Once-a-Day Timolol 0.1% Gel Formulation has an equivalent IOP-lowering efficacy to timolol 0.5% solution

ROULAND JF (a), MOREL-MANDRINO P (b), ELENA PP (b) and POLZER H (c)

IGS meeting 2001; Prague - Czech Republic

(a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) MEDPROJECT PHARMA, Sauerlach, Germany

106

A new long acting ophthalmic formulation of carteolol containing alginic acid

SECHOY O (a), TISSIE G (a), SEBASTIAN C (a), MAURIN F (a), DRIOT JY (a) and TRINQUANT C (a)

Int. J. Pharm. 2000; 207: 109-116 (collaboration)

(a) LABORATOIRE CHAUVIN, Montpellier, France

access to the abstract

105

Therapeutic equivalence of a timolol 0.1% hydrogel (T-Gel 0.1%) QD and aqueous timolol 0.5% BID in reducting the IOP of glaucomatous patients

ELENA PP, ROULAND JF, MOREL-MANDRINO P and POLZER H

ARVO meeting 2000; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2000; 41: S281, abstract No. 2477

89

Intraocular pressure effects of topical rilmenidine in ocular hypertensive animals and in healthy volunteers and glaucoma subjects

NORDMANN JP, ELENA PP and VILAIN C

ISECOPP meeting 1997 Munich – Germany, p. 12

88

Efficacy and local ocular tolerance of Rescula eye drops in glaucoma patients

NORDMANN JP, ROULAND JF, ELENA PP and KAPOK B

ISECOPP meeting 1997 Munich – Germany, p. 27

82

Rilmenidine: safety and efficacy on intraocular pressure in healthy volunteers and glaucoma patients

NORDMANN JP, ELENA PP, MOREL-MANDRINO P, CASTAGNE I and VILAIN C

ARVO meeting 1997; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 1997;38 : S559, abstract No. 2600

75

Assessment of the safety and local pharmacokinetics of 0.15 % gel of ganciclovir (Virgan®) in healthy volunteers

POULIQUEN P (a), ELENA PP (b), MALECAZE F (c), LUYCKX J (a), LANOUE A (a) and GOLDSCHMIDT P (d)

ARVO meeting 1996; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S313, abstract No. 1431

(a) LABORATOIRES THEA, Clermont-Ferrand, France - (b) CLIROPHTHA, Nice, France - (c) Hôpital Purpan, Toulouse, France - (d) Centre Hospitalier Universitaire de la Pitié-Salpêtrière, Paris, France

72

Intraocular pressure effects of topical renin inhibitor CGP 38560 in normal and ocular hypertensive animals and in healthy volunteers and glaucoma subjects

NORDMANN JP, PERCICOT CL, ELENA PP and MATHIS GA

ISECOPP meeting 1995; Geneva – Switzerland, p. 35

71

One drop study to evaluate safety and efficacy of SR43845, a renin inhibitor, in healthy volunteers

DENIS P, NORDMANN JP, ELENA PP, JAILLON P, MATHIS G and SARAUX H

ARVO meeting 1995, Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 1995; 36: S734, abstract No. 3388

70

Evaluation of safety and efficacy of CGP38560, a renin inhibitor, in healthy volunteers and glaucoma subjects

NORDMANN JP, DENIS P, ELENA PP, MATHIS GA, SCHNARR KD, TETZLOFF W and KERKMANN T

ARVO meeting 1995, Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 1995; 36: S719, abstract No. 3317

 

Devices & Evaluations

224

Biocompatibility of MedinGel biodegradable drug delivery system in the eye

SPIS M (a), FERAILLE L (b), ANTONELLI S (b), CIMBOLINI N (b), ELENA PP (b), GAUDRIAULT G (a), PETIT A (a)

ARVO meeting 2014; Orlando, FL - USA. Invest. Ophthalmol. Vis. Sci. 2014, Vol.55, 5273. doi:

(a) MEDINCELL, Jacou, France - (b) IRIS PHARMA, Nice, France

access to the abstract

185

Plasma and ocular pharmacokinetic study comparing 3 µL micro-drop to typical 40 µL drop volume of timolol 0.5% in pigmented rabbits

VAN DER HEIDEN H (a,b), AMAR T (c) and LICHTENAUEUR W (a)

ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 453 - Poster D0072

(a) MU-DROP, Apeldoorn, Netherlands - (b) ZAMB, Hospital Pharmacy, Tilburg, Netherlands - (c) IRIS PHARMA, Nice, France

174

Assessment of a new device for conjunctival impression

ROY P (a), CIMBOLINI N (b), ANTONELLI S (b), FERAILLE L (b), ELENA PP (b) and BAUDOUIN C (c)

MCLOSA meeting 2012; London - England

(a) OPIA TECHNOLOGIES, Paris, France - (b) IRIS PHARMA, Nice, France - (c) Ophthalmology, Quinze-Vingts Hospital, Paris, France

166

Assessment of a new device for conjunctival impression

ROY P (a), CIMBOLINI N (b), ANTONELLI S (b), FERAILLE L (b) ELENA PP (b) and BAUDOUIN C (c)

ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1868 - Poster A331

(a) OPIA TECHNOLOGIES, Paris, France - (b) IRIS PHARMA, Nice, France - (c) Ophthalmology, Quinze-Vingts Hospital, Paris, France

access to the abstract

165

Assessment of a new device for conjunctival impression

ROY P (a), CIMBOLINI N (b), ANTONELLI S (b), FERAILLE L (b) and ELENA PP (b)

Oral presentation. ISOPT meeting 2011; Vienna, Austria

(a) OPIA TECHNOLOGIES, Paris, France - (b) IRIS PHARMA, Nice, France

164

Explorations et imagerie rétinienne

BENCHABOUNE M (a)

STO meeting 2011; Tunis - Tunisia (Oral Communication in French)

(a) IRIS PHARMA, Nice, France

163

Adaptative optics imaging in age-related macular degeneration

GOCHO-NAKASHIMA K (a), BENCHABOUNE M (b), ULLERN M (a), LAMORY B (c) , CHATEAU N (c) , SAHEL JA (a) and PAQUES M (a)

EVER meeting 2011; Crete - Greece (Oral Communication)

(a) INSERM 503, Paris, France - (b) IRIS PHARMA, Nice, France - (c) IMAGINE EYES, Orsay, France

access to the abstract

162

In vivo microscopic imaging of drusen using adaptive optics

LAMORY B (a), NAKASHIMA K (b), BENCHABOUNE M (b,c), ULLERN M (b), VUAILLAT E (a), SAHEL JA (b) and PAQUES M (b)

ARVO meeting 2011; Fort Lauderdale, FL - USA. ARVO e-abstract No. 4469/A218

(a) IMAGINE EYES, Orsay, France - (b) INSERM 503, Paris, France - (c) IRIS PHARMA, Nice, France

access to the abstract

161

Evaluation of membrane material for impression cytology

ROY P (a), CIMBOLINI N (b), FERAILLE L (b), KECHAD M (b) and ELENA PP (b)

ARVO meeting 2011; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1937 - Poster D918

(a) OPIA TECHNOLOGIES, Paris, France - (b) IRIS PHARMA, Nice, France

access to the abstract

147

Ocular tolerability of iontophoresis

ROY P (a), ELENA PP (b), VIAUD K (b), CAILLAUD T (b) and CALIAS P

ARVO meeting 2007; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5800

(a) EYEGATE PHARMACEUTICALS, Waltham, USA - (b) IRIS PHARMA, Nice, France

146

New evaluation techniques in ocular surface diseases : comparison of antiallergic drugs using in vivo confocal microscopy for assessing late response of induced ocular anaphylaxis in the guinea pig

FERAILLE L (a)

Oral presentation. EVER meeting 2007; Portoroz, Slovenia

(a) IRIS PHARMA, Nice, France

145

Update on drug delivery systems used in the anterior part of the eye : review of the new drug delivery systems for the anterior chamber

ELENA PP (a)

Oral presentation. ESCRS meeting 2007; Stockholm, Sweden

(a) IRIS PHARMA, Nice, France

144

Trend of prescription of silicon hydrogel lens by ophthalomologists and lens assessment by patients

CROS BOIDEVEZI M (a), STEVE L (a), JOUVENCEL R (a) and CLIROPHTHA (b)

29th IEEE EMBS Annual International Conference 2007; Lyon - France

(a) CIBA VISION France, Paris, France - (b) CLIROPHTHA, Nice, France

143

A new method for intra ocular pressure in vivo measurement: first clinical trials

DUBOIS P, ZEMMOURI J, ROULAND JF, ELENA PP, LOPES R and PUECH P

29th IEEE EMBS Annual International Conference 2007; Lyon - France

137

Enquête prospective, nationale, multicentrique auprès de 345 patients anciens et nouveaux porteurs sur la santé oculaire, la performance visuelle et la satisfaction des lentilles 02 OPTIX TORIC

DELFOUR-MALECAZE M (a), STEVE L (b) and CLIROPHTHA (c)

Réflexions Ophtalmol. 2006; 95: 50-53

(a) Toulouse, France (b) CIBA VISION France, Paris, France - (c) CLIROPHTHA, Nice, France

135

Trend of prescription of silicone hydrogel lens by ophthalmologists and lens assessment by patients

CROS BOIDEVEZI M (a), STEVE L (a), JOUVENCEL R (a) and CLIROPHTHA (b)

36th ECLSO Congress 2006; Dubrovnik - Czech Republic. Abstract No. 9

(a) CIBA VISION France, Paris, France - (b) CLIROPHTHA, Nice, France

134

Etude comparative des implants Alcon asphériques (SN60WF) versus standards (SN60AT)

MONTARD M

Safir meeting 2006. Paris - France (collaboration).

131

Pharmacokinetics of clonidine after a single application of transscleral iontophoresis in rabbits

CAILLAUD T (a), ROY P (b), VIAUD K (a) and ELENA PP (a)

ARVO meeting 2006; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2006; 47: ARVO e-abstract No. 5109

(a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France

130

Influence of solution composition and electrode design on transscleral iontophoresis delivery of dexamethasone disodium phosphate

ROY P (a), VIAUD K (b), CAILLAUD T (b) and ELENA PP (b)

ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5110

(a) EYEGATE, Paris, France - (b) IRIS PHARMA, Nice, France

129

Evaluation of ocular tolerability of repetitive corneal-scleral iontophoresis in pigmented rabbits

ELENA PP (a), ROY P (b), VIAUD K (a) and CAILLAUD T (a)

ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5094

(a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France

125

Une nouvelle méthode de mesure de la pression intraoculaire

DUBOIS P (a), ZEMMOURI J (b), ROULAND JF (c) and ELENA PP (d)

IRBM 26; 4: 285-290

(a) Institut de technologie médicale, CHRU, Lille, France - (b) Laboratoire de spectroscopie hertzienne, USTL, Villeneuve d’Ascq, France - (c) Hôpital Huriez, Lille, France - (d) IRIS PHARMA, Nice, France

access to the abstract

68

Non-invasive measurement of ocular temperature by using infrared thermographic analysis in immune and non-immune allergy models

ELENA PP, KHOSRAVI E and HARITON C

ISECOPP meeting 1995 Geneva - Switzerland, p. 60

47

La radioautographie en ophtalmologie: méthodologie et applications à l'étude des récepteurs oculaires et à l'hybridation in situ

DENIS P, ELENA PP, NORDMANN JP, DUSSAILLANT M, LAPALUS P, SARAUX H and ROSTENE W

"Physiologie, Pathologie et Génétique Oculaire." CHRISTEN Y AND DROIX-LEFAIX MT ed. (Springer Verlag, Paris, 1991), 105-113

34

Localization and characterization of receptors in human and animal eyes by “ in vitro ” autoradiography

ELENA PP, DENIS P, FREDJ-REYGROBELLET D, ROSTENE W and LAPALUS P

ISER meeting 1990; Helsinki - Finland, p 228, abstract No. 803

 

Formulation & Drug Delivery

206

Binding to ocular albumin as a half-life extension. Principle for intravitreally injected drugs: evidence from mechanistic rat and rabbit studies

FUCHS H (a) and IGNEY F (a)

J. Ocul. Pharmacol. Ther. 2017; DOI: 10.1089/jop.2016.0083 (collaboration)

(a) BOEHRINGER INGELHEIM PHARMA GmbH & Co. KG, Biberach an der Riss, Germany

197

Long-term tolerance of preservative-free eye drops containing macrogol hydroxystearate as an excipient

Tolérance à long terme d’un collyre sans conservateur contenant comme excipient du macrogol hydroxystearate

VIAUD K (a), LEFRANC-JULLIEN S (a), FERAILLE L (a) and ELENA PP (a)

J. Fr. Ophtalmol. 2015; Doi : 10.1016/j.jfo.2015.09.011

(a) IRIS PHARMA, Nice, France 

access to the abstract

189

In vivo ocular tolerance of a new preservative-free eye drop formulation in rabbits

QUENTRIC Y (a), VIAUD K (a), LEFRANC-JULLIEN S (a), FERAILLE L (a) and ELENA PP (a)

ARVO meeting 2015; Denver, CO - USA. ARVO e-abstract No. 802 - Poster D0264

(a) IRIS PHARMA, Nice, France 

download the poster   ⇒ access to the abstract

188

The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye

BARABINO S (a), ANTONELLI S (b), CIMBOLINI N (b), MAURO V (b) and BOUZIN M (b)

Invest. Ophthalmol. Vis. Sci. 2014; 55:6499-6504 doi:10.1167/iovs.14-14548

(a) CLINICA OCULISTICA, GENOCA, ITALY - (b) IRIS PHARMA, Nice, France

access to the abstract

185

Plasma and ocular pharmacokinetic study comparing 3 µL micro-drop to typical 40 µL drop volume of timolol 0.5% in pigmented rabbits

VAN DER HEIDEN H (a,b), AMAR T (c) and LICHTENAUEUR W (a)

ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 453 - Poster D0072

(a) MU-DROP, Apeldoorn, Netherlands - (b) ZAMB, Hospital Pharmacy, Tilburg, Netherlands - (c) IRIS PHARMA, Nice, France

184

Ocular pharmacokinetic study comparing ramipril and ramiprilat formulations administered orally or topically in pigmented rabbits

QUENTRIC Y (a), AMAR T (a), BARRE N (a), FERAILLE L (a) and REKIK R (b)

ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 2360 - Poster B0036

(a) IRIS PHARMA, Nice, France - (b) OPHTHALMOLOGY CLINIC, Tunis, Tunisia

182

Biocompatibility of MedinGel biodegradable drug delivery system in the eye

SPIS M (a), FERAILLE L (b), ANTONELLI S (b), CIMBOLINI N (b),  ELENA PP (b),  GAUDRIAULT G (a) and PETIT A (a)

ARVO meeting 2014; Orlando, FL - USA. Invest. Ophthalmol.Vis. Sci 2014; 55, 5273. doi:

(a) MEDINCELL, Jacou, France - (b) IRIS PHARMA, Nice, France

access to the abstract

179

Impact of the routes of administration on the effects of cyclosporine in an experimental rat model of dry eye

CIMBOLINI N (a), GRILLO-ANTONELLI S (a), FERAILLE L (a), MARGARON P (a) and ELENA PP (a)

ISOPT meeting 2013; Paris – France

(a) IRIS PHARMA, Nice, France

download the poster

178

CLS1001 suprachoroidal injectable suspension of triamcinolone acetonide is well tolerated in the albino rabbit

VERHOEVEN R (a), VIAUD-QUENTRIC K (b), CACCIAMANI F (b) and PATEL S (a)

American College of toxicology 2013 San Antonio, Texas - USA. Poster P505

(a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France

177

Suprachoroidal microinjection of triamcinolone acetonide is well tolerated in the albino rabbit

VERHOEVEN R (a), PATEL S (a),  VIAUD-QUENTRIC K (b), CACCIAMANI F (b), AMAR T (b) and YERXA B (a)

ARVO meeting 2013; Seattle, WA - USA. ARVO e-abstract No. 119 - Poster C0124

(a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France

access to the abstract

169

Augmentation of the ocular penetration of dexamethasone with β-blocker and α-agonist co-administration

ELENA PP (a), SENSEBY F (a), BERMON F (a), CHARFEDDINE R (b) and REKIK R (c)

EVER meeting 2012; Nice - France. Poster F107

(a) IRIS PHARMA, Nice, France - (b) UNIMED, Sousse, Tunisie - (c) Ophthalmology Clinic, Tunis, Tunisia

access to the abstract

168

Anti-inflammatory effects of glucocorticoids on endotoxin-induced uveitis in rats: effects of the mode of administration

ELENA PP (a), CIMBOLINI N (a), ANTONELLI S (a), DUBOS H (a), FERAILLE L (a) and MARGARON P (a)

ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 6285 - Poster D1145

(a) IRIS PHARMA, Nice, France

download the poster   ⇒ access to the abstract

167

Assessment of intra-ocular pressure lowering effect of novel gel formulations of latanoprost and timolol in nonhuman primates following topical delivery

GOODY RJ (a), WHITTAKER S (a), HENRY S (a), BROOKES R (a), STRUHARIK M (a), BERMON F (b), MARGARON P (b), POLZER H (c) and LAWRENCE MS (a)

ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1968 - Poster D812

(a) RXGEN, Hamden, CT, USA - (b) IRIS PHARMA, Nice, France - (c) MEDPROJECT PHARMA, Bayern, Germany

access to the abstract

157

Designing dendrimers for ocular delivery

SPATARO G (a,b), MALECAZE F (c), TURRIN CO (a,b), SOLER V (c), DUHAYON C(a,b), ELENA PP (d), MAJORAL JP (a,b) and CAMINADE AM (a,b)

Eur. J. Med. Chem. 2010; 45: 326-334

(a) CNRS, Laboratoire de Chimie de Coordination, Toulouse, France - (b) Universite de Toulouse, Toulouse, France -  (c) Hôpital Purpan, Toulouse, France - (d) IRIS PHARMA, Nice, France

access to the abstract

156

Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation

AKPEK EK (a), VITTITOW J (b), VERHOEVEN RS (b), BRUBAKER K (b), AMAR T (c), POWELL KD (d), BOYER JL (b) and CREAN C (b)

J. Ocul. Pharmacol. Ther. 2009; 25: 433-439

(a) THE WILMER EYE INSTITUTE, Johns Hopkins Hospital, Baltimore, USA - (b) INSPIRE PHARMACEUTICALS, Durham, USA - (c) IRIS PHARMA, Nice, France - (d) ENTHALPY ANALYTICAL, Durham, USA

access to the abstract

153

Snapshot test for investigating gels of anti-glaucoma compounds as topical formulations

ELENA PP (a), POLLIN C (a), BERMON F (a), AMAR T (a), CAILLAUD T (a) and POLZER H (b)

ARVO meeting 2009; Fort Lauderdale, FL - USA. ARVO e-abstract No. 6002

(a) IRIS PHARMA, Nice, France - (b) MEDPROJECT PHARMA, Bayern, Germany

access to the abstract

148

Cationic oil-in-water emulsion as an improved cyclosporine ocular vehicle for vernal keratoconjuctivitis sicca (VKC)

LAMBERT G (a) and RABINOVICH-GUILATT L (a)

ARVO meeting 2007; Fort Lauderdale, FL - USA. ARVO poster No. 2301/B999 (collaboration)

(a) NOVAGALI PHARMA SA, Evry, France

147

Ocular tolerability of iontophoresis

ROY P (a), ELENA PP (b), VIAUD K (b), CAILLAUD T (b) and CALIAS P

ARVO meeting 2007; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5800

(a) EYEGATE PHARMACEUTICALS, Waltham, USA - (b) IRIS PHARMA, Nice, France

145

Update on drug delivery systems used in the anterior part of the eye: review of the new drug delivery systems for the anterior chamber

ELENA PP (a)

ESCRS meeting 2007; Stockholm, Sweden. Oral presentation

(a) IRIS PHARMA, Nice, France

143

A new method for intra ocular pressure in vivo measurement: first clinical trials

DUBOIS P, ZEMMOURI J, ROULAND JF, ELENA PP, LOPES R and PUECH P

29th IEEE EMBS Annual International Conference 2007; Lyon - France

131

Pharmacokinetics of clonidine after a single application of transscleral iontophoresis in rabbits

CAILLAUD T (a), ROY P (b), VIAUD K (a) and ELENA PP (a)

ARVO meeting 2006; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2006; 47: ARVO e-abstract No. 5109

(a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France

130

Influence of solution composition and electrode design on transscleral iontophoresis delivery of dexamethasone disodium phosphate

ROY P (a), VIAUD K (b), CAILLAUD T (b) and ELENA PP (b)

ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5110

(a) EYEGATE, Paris, France - (b) IRIS PHARMA, Nice, France

129

Evaluation of ocular tolerability of repetitive corneal-scleral iontophoresis in pigmented rabbits

ELENA PP (a), ROY P (b), VIAUD K (a) and CAILLAUD T (a)

ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5094

(a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France

124

Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients

RENARD P (a), KOVALSKI JL (b), COCHEREAU I (c), JAULERRY S (d), WILLIAMSON W (e), ELENA PP (f), LABLACHE COMBIER M (g), ALLAIRE C (g) and SIOU-MERMET R (g)

Graefe's Arch. Clin. and Exp. Ophthalmol. 2005; 243: 1221-1227

(a) Institut Vernes, Paris, France - (b) HIA Clermont Tonnerre, Brest, France - (c) CHRU, Angers, France - (d) CH Tarbes Vic Bigorre, Tarbes, France - (e) CH François Mitterrand, Pau, France - (f) IRIS PHARMA-CLIROPHTHA, Nice, France - (g) BAUSCH & LOMB, Paris, France

⇒ to read the abstract

122

Ocular hypotensive effect of a new “once-daily” eye-dops formulation of 0.5% timolol (Timolast™) in comparison to Timoptol® 0.5% administered twice-daily

ROULAND JF (a), MOREL-MANDRINO P (b), ELENA PP (b), DE GREGORIO F (c), BAROZZI C (c), FEDELI E (c) and FERREIRA VD (c)

ISOPT meeting 2004; Monte-Carlo – Monaco

(a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) TUBILUX PHARMA SpA, Roma, Italy

121

Intérêt d’une nouvelle formulation de diclofénac sans conservateur pour la surface oculaire

CHIAMBARETTA F (a), CREUZOT-GARCHER C (b), PILON F (a), POULIQUEN P (c), REBIKA H (c), DUBRAY C (d) and RIGAL D (a)

J. Fr. Ophtalmol. 2004; 27, 7, 739-744 (collaboration)

(a) Hôpital Gabriel Montpied, Clermont-Ferrand, France - (b) CHU de Dijon, Dijon, France - (C) LABORATOIRES THEA, Clermont-Ferrand, France - (d) Unité de Pharmacologie Clinique, Centre de Recherche en Nutrition Humaine, Clermont-Ferrand, France

access to the article

120

Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost

BRON A, VELASQUE L, REBICA H, POULIQUEN P, ELENA PP and ROULAND JF

J. Fr. Ophtalmol. 2004; 27(9 Pt 1): 971-7

access to the abstract

119

Non-inferiority, in the intra-ocular pressure (IOP)-lowering effect, of a new eye-drops formulation of 0.5% timolol (Timolast™) instilled once-daily versus 0.5% Timoptol®, instilled twice-daily, for 4 months in ocular hypertensive or glaucomatous patients

ROULAND JF (a), MOREL-MANDRINO P (b), DE GREGORIO F (c), BAROZZI C (c) and FEDELI E (c)

ARVO meeting 2004; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 2080

(a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) TUBILUX PHARMA SpA, Roma, Italy

118

Comparison of carteolol plasmatic levels after repeated instillations of long acting and regular formulations of carteolol 2% in glaucomatous patients

ALLAIRE CM, RENARD P, KOVALSKI J, COCHEREAU I, JAULERRY S, WILLIAMSON W, ELENA PP and LABLACHE-COMBIER M

ARVO meeting 2004; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 957

117

Efficacy and safety of diclofenac 0.1% ABAK® versus preserved diclofenac® 0.1% eye drops in controlling post-cataract surgery inflammation

GOLDSCHMIDT P, ELENA PP, BALDWIN H, DELVAL L and COLIN J

ARVO meeting 2004; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 294

112

Timolol 0.1% gel (Nyogel 0.1%®) once daily versus conventional timolol 0.5% solution twice daily: a comparison of efficacy and safety

ROULAND JF (a), MOREL-MANDRINO P (b), ELENA PP (b), POLZER H (c) and SUNDER RAJ P (d)

Ophthalmologica 2002; 216: 449-454

(a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) MEDPROJECT PHARMA, Sauerlach, Germany - (d) NOVARTIS OPHTHALMICS, Farnborough, UK

access to the abstract

109

A Novel Once-a-Day Timolol 0.1% Gel Formulation has an equivalent IOP-lowering efficacy to timolol 0.5% solution

ROULAND JF (a), MOREL-MANDRINO P (b), ELENA PP (b) and POLZER H (c)

IGS meeting 2001; Prague - Czech Republic

(a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) MEDPROJECT PHARMA, Sauerlach, Germany

107

A new long acting ophthalmic formulation of carteolol containing alginic acid

SECHOY O, TISSIE G, SEBASTIAN C, MAURIN F, DRIOT JY and TRINQUANT C

Int. J. Pharm. 2000; 207: 109-116 (collaboration)

106

A new long acting ophthalmic formulation of carteolol containing alginic acid

SECHOY O (a), TISSIE G (a), SEBASTIAN C (a), MAURIN F (a), DRIOT JY (a) and TRINQUANT C (a)

Int. J. Pharm. 2000; 207: 109-116 (collaboration)

(a) LABORATOIRE CHAUVIN, Montpellier, France

access to the abstract

105

Therapeutic equivalence of a timolol 0.1% hydrogel (T-Gel 0.1%) QD and aqueous timolol 0.5% BID in reducting the IOP of glaucomatous patients

ELENA PP, ROULAND JF, MOREL-MANDRINO P and POLZER H

ARVO meeting 2000; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2000; 41: S281, abstract No. 2477

103

Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits

PISELLA PJ (a,b), FILLACIER K (d), ELENA PP (e), DEBBASCH C (b,c) and BAUDOUIN C (a)

Ophthalmic Res. 2000; 32: 3-8

(a) Department of Ophthalmology, Ambroise Paré Hospital, APHP, Paris, France - (b) Toxicology Laboratory, University of Paris-V René Descartes, Paris, France - (c) Department of Cellular Pharmacotoxicology, XV-XX Hospital, Paris, France - (d) Department of Ophthalmology, University of Nice, France - (e) IRIS PHARMA, Nice, France

access to the article

101

Evaluation of a novel carteolol eye-drops with alginic acid as long action promoter

TISSIE G, SEBASTIAN C, MAURIN F, SECHOY O, DRIOT JY, ELENA PP and TRINQUAND C

EVER meeting 2000; Palma de Mallorca, Spain. Ophthalmic Res. 2000; 32(S2): 29, abstract No. 214

100

Alginic acid effect on ocular distribution of carteolol after a single instillation in pigmented rabbits

SEBASTIAN C, TISSIE G, DRIOT JY, ELENA PP and TRINQUAND C

EVER meeting 2000; Palma de Mallorca, Spain. Ophthalmic Res. 2000; 32(S2): 28, abstract No. 215

86

Effects of different formulations of mitoxantrone (solutions, nanospheres, liposomes) on glaucoma surgery in rabbits

TILLEUL P, DENIS P, MAIGNEN F, ELENA PP, NORDMANN JP, LEVERGE R and ROSTENE W

Ophthalmic Res. 1997; 29: 218-226

access to the abstract

80

Antiproliferative activity of a liposomal delivery system of mitoxantrone on rabbit subconjunctival fibroblasts in an ex-vivo model

MAIGNEN F, TILLEUL P, BILLARDON C, XU-VAN OPSTAL WY, PELAPRAT D, ELENA PP, DENIS P and ROSTENE W

J. Ocul. Pharmacol. Ther. 1996; 12: 289-298

75

Assessment of the safety and local pharmacokinetics of 0.15 % gel of ganciclovir (Virgan®) in healthy volunteers

POULIQUEN P (a), ELENA PP (b), MALECAZE F (c), LUYCKX J (a), LANOUE A (a) and GOLDSCHMIDT P (d)

ARVO meeting 1996; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S313, abstract No. 1431

(a) LABORATOIRES THEA, Clermont-Ferrand, France - (b) CLIROPHTHA, Nice, France - (c) Hôpital Purpan, Toulouse, France - (d) Centre Hospitalier Universitaire de la Pitié-Salpêtrière, Paris, France

74

Ocular bioavailability of ganciclovir gel, an anti-herpetic formulation, after topical administration to intact or removed corneal epithelium of rabbit eyes

KHOSRAVI E, ELENA PP, GOLDSCHMIDT P and LUYCKX J

ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S81, abstract No. 383

60

Distribution of ganciclovir in the anterior uvea after topical application of 0.15 % ganciclovir gel to intact and HSV-infected eyes of rabbits

ELENA PP, GOLDSCHMIDT P, CHAST F, SAUVAGEON H, LUYCKX J and KHOSRAVI E

ARVO meeting 1994; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1994; 35: 1682, abstract No. 1984

56

Bioequivalence between timolol maleate formulated in ophthalmic solution (Timoptol®) and in a novel gel vehicle (T-Gel)

ELENA PP, POLZER H and KHOSRAVI E

ARVO meeting 1993; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1993; 34: 1490, abstract No. 3902

55

Ocular pharmacokinetics of topically-applied ganciclovir in rabbits with intact or removed corneal epithelium

CHIBRET H, ELENA PP and KHOSRAVI E

ARVO meeting 1993; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1993; 34: 1050, abstract No. 1712

50

Effect of diclofenac sodium and diclofenac sodium SDU eyedrops on prostaglandin concentrations in aqueous humor of rabbits after extracapsular surgery

ELENA PP, ULRICH E, TSCHALAR Y, LAPALUS P, ETTAICHE M and KHOSRAVI E

ISER meeting 1992; Stresa - Italy. Exp. Eye Res. 1992; 55: S54, abstract No. 183

49

Ocular pharmacokinetics of two preservatives, benzalkonium chloride or benzoxonium chloride, after instillation in the pigmented rabbit

ELENA PP, KHOSRAVI E, LAPALUS P and ULRICH E

ISER meeting 1992; Stresa - Italy. Exp. Eye Res. 1992; 55: S54, abstract No. 182

 

Basic Research & Reports

211

Transform your macroscope into an ultramacroscope for 3D imaging of cleared organs

GESSON M (a), KECHAD M (b), MAUCLERT N (c), GIRARD P (c), ROUSSEL A (c), PIERRE O (d), GROSJEAN I (e), BRAU F (f)

Focus on Microscopy meeting 2017; Bordeaux - France. Poster No P2-A/26

(a) CNRS, INSERM, Institut Biologie Valrose, Nice, France - (b) IRIS PHARMA, La Gaude, France - (c) OCA, Service de Mécanique Mutualisé, France - (d) IINRA, Institut Sophia Agrobiotech, Biot, France - (e) INSERM, Institut de Recherche sur le Cancer et le Vieillissement, Nice, France - (f) CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France

205

Norbixin protects retinal pigmented epithelium cells and photoreceptors against A2E-mediated phototoxicity in vitro and in vivo

FONTAINE V (a), MONTEIRO E (a), BRAZHNIKOVA E (a), LESAGE L (a), BALDUCCI C (b), GUIBOUT L (b), FERAILLE L (c), ELENA PP (c), SAHEL JA (a), VEILLET S (b), LAFONT R (b)

PLOS ONE 11(12): e0167793. doi: 10.1371/journal.pone.0167793

(a) INSTITUT DE LA VISION, Paris, France - (b) BIOPHYTIS, Paris, France - (c) IRIS PHARMA, La Gaude, France

access to the article

186

Regulatory Issues related to preclinical animal research

ELENA PP (a)

ARVO meeting 2014; Orlando, FL - USA. Oral communication

(a) IRIS PHARMA, Nice, France

175

Report of the TFOS/ARVO symposium on global treatments for dry eye disease: an unmet need

SULLIVAN D (a), HAMMITT K (b), SCHAUMBERG D (c), SULLIVAN B (d), BEGLEY C (e), GJORSTRUP P (f), GARRIGUE JS (g), NAKAMURA M (h), QUENTRIC Y (i), BARABINO S (j), DALTON M (k) and NOVACK G (l)

The Ocular Surface. Special Article. April 2012; 10(2): 108-116

(a) SCHEPENS EYE RESEARCH INSTITUTE, Boston, MA, USA - (b) SJOGREN’s SYNDROME FOUNDATION, Bethesda, MD, USA - (c) BRIGHAM AND WOMEN'S HOSPITAL and HARVARD MEDICAL SCHOOL, Boston, MA, USA - (d) TEARLAB Corporation, San Diego, CA, USA - (e) SCHOOL OF OPTOMETRY, Bloomington, IN, USA - (f) RESOLVYX PHARMACEUTICALS, Bedford, MA, USA - (g) NOVAGALI PHARMA, Evry, France - (h) SANTEN PHARMACEUTICAL Co, Nara, Japan - (i) IRIS PHARMA, Nice, France - (j) CLINICA OCULISTICA, Genova, Italy - (k) DALTON & ASSOCIATES, Reading, PA, USA - (l) PHARMA LOGIC, San Rafael, CA, USA

access to the abstract

164

Explorations et imagerie rétinienne

BENCHABOUNE M (a)

STO meeting 2011; Tunis - Tunisia. Oral Communication in French

(a) IRIS PHARMA, Nice, France

163

Adaptive optics imaging in age-related macular degeneration

GOCHO-NAKASHIMA K (a), BENCHABOUNE M (b), ULLERN M (a), LAMORY B (c), CHATEAU N (c), SAHEL JA (a) and PAQUES M (a)

EVER meeting 2011; Crete - Greece. Oral Communication

(a) INSERM 503, Paris, France - (b) IRIS PHARMA, Nice, France - (c) IMAGINE EYES, Orsay, France

access to the abstract

162

In vivo microscopic imaging of drusen using adaptive optics

LAMORY B (a), NAKASHIMA K (b), BENCHABOUNE M (b,c), ULLERN M (b), VUAILLAT E (a), SAHEL JA (b) and PAQUES M (b)

ARVO meeting 2011; Fort Lauderdale, FL - USA. ARVO e-abstract No. 4469/A218

(a) IMAGINE EYES, Orsay, France - (b) INSERM 503, Paris, France - (c) IRIS PHARMA, Nice, France

access to the abstract

159

Dry Eye Syndrome: the regulatory challenge. Clinical trial and regulatory challenges faced by Iris Pharma in the development of dry eye therapies

QUENTRIC Y (a)

TFOS Global Dry Eye Experts' meeting 2010; Florence - Italy. Oral Communication

(a) IRIS PHARMA, Nice, France

158

Rôle des oligoéléments (Se, Zn) dans la prévention de la DMLA : le point en 2010

BENCHABOUNE M (a)

SFVB/SFERETE/ATERET meeting 2010; Monastir - Tunisia. Oral Communication in French

(a) IRIS PHARMA, Nice, France

155

Associer les patients atteints de DMLA à la recherche, est-ce possible?

BENCHABOUNE M (a)

Vu et Entendu. 2009; 2: 4

(a) IRIS PHARMA, Nice, France

access to the article

150

La recherche biomédicale en France : ce qui a changé depuis 2004

CLERGET-CHOSSAT N (a), CAILLAUD T (a) and ELENA PP (a)

J. Fr. Ophtalmol. 2008; 31: 80-86

(a) IRIS PHARMA, Nice, France

225

Ether-Lipid-Deficient-Mice Display Pigmentary Glaucoma Features as Well as Abnormal Retinal Vasculature

ACAR N (a), SICARD P (b), SCHNEBELEN C (a), CIMBOLINI N (c), IVINGS L (a), GRILLO-ANTONELLI S (c), ROCHETTE L (b), CREUZOT-GARCHER CP (a,d), BRETILLON L (a), JUST WW (e)

ARVO meeting 2007; Fort Lauderdale, FL - USA. Investigative Ophthalmology & Visual Science May 2007, Vol.48, 2978. doi:

(a) INRA, Dijon, France - (b) Faculties of Medicine and Pharmacy, Dijon, France - (c) IRIS PHARMA, Nice, France - (d) University Hospital, Dijon, France - (e) Biochemie Zentrum Heidelberg (BZH), Heidelberg, Germany

63

Central nervous system control of intraocular pressure

DENIS P, NORDMANN JP, ELENA PP, SARAUX H, and LAPALUS P

Fundam. Clin. Pharmacol. (France) 1994; 8: 230-237

57

Physiological roles of dopamine and neuropeptides in the retina

DENIS P, NORDMANN JP, ELENA PP, DUSSAILLANT M, SARAUX H, and LAPALUS P

Fundam. Clin. Pharmacol. (France) 1993; 7: 293-304